Boron containing small molecules

• US 9,499,570 B2
• Filed: 09/11/2015
• Issued: 11/22/2016
• Est. Priority Date: 01/27/2010
• Status: Active Grant

• Current Assignee: Anacor Pharmaceuticals, Inc. (Pfizer Inc.)
• Original Assignee: Anacor Pharmaceuticals, Inc. (Pfizer Inc.)
• Inventors: Jarnagin, Kurt, Akama, Tsutomu
• Primary Examiner(s): REESE, HEIDI L
• Application Number:
  US14/852,122
• Publication Number:
  US 20150376210A1
• Time in Patent Office: 438 Days
• Field of Search: None
• US Class Current: 1/1
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 33/10 Anthelmintics
• CPC Class Codes: A61P 33/12 Schistosomicides
• CPC Class Codes: C07F 5/025 Boronic and borinic acid compounds
• CPC Class Codes: C07F 5/04 Esters of boric acids

Abstract

Compounds, pharmaceutical formulations, and methods of treating anti-inflammatory conditions and/or helminth-associated diseases are disclosed.

Claims

1. A method of decreasing the release of a cytokine or a chemokine, the method comprising:

contacting a cell with the compound having a structure according to a formula which is selected from the group consisting of;

2. A method of treating psoriasis, atopic dermatitis, rheumatoid arthritis, an inflammatory bowel disease, asthma and chronic obstructive pulmonary disease, in an animal, the method comprising administering to the animal a therapeutically effective amount of the compound having a structure according to a formula which is selected from the group consisting of:

3. A method of inhibiting a phosphodiesterase (PDE), the method comprising:

contacting the phosphodiesterase with a compound having a structure according to a formula which is selected from the group consisting of;

4. The method of claim 3, wherein said phosphodiesterase is phosphodiesterase4 (PDE4).